

# JAGSONPAL PHARMACEUTICALS LIMITED

CIN: L74899DL1978PLC009181

Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049

Phone: 011-46181100 & 46109900, FAX: 011-26498341

Website: [www.jagsonpal.com](http://www.jagsonpal.com) , E-mail: [nandita.singh@jagsonpal.com](mailto:nandita.singh@jagsonpal.com)

Date: June 29 <sup>th</sup> , 2020	
The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager Listing Agreement The BSE Limited Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
<b>CM Quote : JAGSNPHARM</b>	<b>SCRIP Code : 507789</b>
<b>Subject: Disclosure of material impact of COVID-19 pandemic on the Company under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR Regulations)</b>	

Dear Madam and Sir

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to advisory issue by Securities and Exchange Board of India (SEBI) vide its circular SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020, in view of the outbreak of the Coronavirus (CoVID-19) pandemic and in compliance with the directives / orders issued by the State / Central Government authorities (from time to time) and keeping in mind the safety and well-being of all the employees and stakeholders, the Company's Registered Office including all branches operations are temporarily shut down.

We are trying our best to minimize COVID 19 impact on the company. Employees are being encouraged to work-from-home on pan-India basis except those handling essential services. Our investments in digitisation through ERP is helping us to shift some of our operations to remote working environment, thus, keeping employees safety as top priority during this crisis.

The non-operation of Metro Trains in Delhi, due to which the Company's officer and employees are unable to restart the office till further direction, issued by the State / Central Government authorities.

All the statutory documents, Computer Servers, files and other data of the Company are situated at the office and the officers have limited manpower resources. Due to which the Company is doing its internal financial operation (such as finalization of Accounts, carrying out the statutory audit and all other statutory Compliance work for preparation of financial results) with limited resources only. The Officers are endeavoring to carry out to the extent possible compliances which can be managed with the available details from home.

**Factory: 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953**

# **JAGSONPAL PHARMACEUTICALS LIMITED**

**CIN: L74899DL1978PLC009181**

**Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049**

**Phone: 011-46181100 & 46109900, FAX: 011-26498341**

**Website: [www.jagsonpal.com](http://www.jagsonpal.com) , E-mail: [nandita.singh@jagsonpal.com](mailto:nandita.singh@jagsonpal.com)**

FY20 started well with strong business momentum, with key project wins and focus on timely execution. While the COVID 19 impact on Q4FY20 numbers is yet to be quantified, we do not expect it to be significant on the top-line for the financial FY20. We are confident of achieving the outlook given for financial performance of FY20, but some impact can be felt on the new orders and collection performance, as last month of the financial year plays an important role towards improving collections.

To the extent possible, company has tried to negate the impact through remote working. Soon after normal working is possible in our operations, we will attempt to reach full capacity at the earliest, as most of the work by the company is done by in house teams.

Despite of the impact of the pandemic, the Company had to continue to incurring fixed expenses like salaries and other fixed expenses etc. which affecting overall profitability of the Company and that effect would be impacted for the coming two quarters of the Company.

We are also hopeful that fixed cost during lockdown period can be largely recovered in remaining part of the year and savings through cost reduction wherever possible. Given the uncertainty, the overall impact in future on the operations of the company and on our client, which may also affect us in turn, is not immediately assessable. Our business model will help us to navigate through these difficult times and gives us confidence to emerge stronger soon.

However, to find out the exact impact of COVID-19 on the operations of the Company and financial resources, profitability etc., we required more time and studies. The Board and the Management are monitoring the situation as it evolves and will take all possible measures to protect the interests of the Company and its Stakeholders. Since the situation is exceptional it may not be possible to estimate the future impact on its operations with certainty.

This is for your information and records.

Thanking You,

**For Jagsonpal Pharmaceuticals Limited**



Nandita Singh  
Company Secretary & Compliance Officer  
M. No. A48520